Abrupt Discontinuation of GLP-1 Medications Erases Life-Saving Cardiovascular Benefits According to WashU Study

WashU study finds that stopping GLP-1 medications like Ozempic and Mounjaro even briefly increases the risk of heart attack and stroke by up to 22%.

By: AXL Media

Published: Mar 18, 2026, 3:05 PM EDT

Source: Information for this report was sourced from Washington University in St. Louis

The Hidden Dangers of Treatment Interruption

As GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound surge in popularity for weight loss and diabetes management, a critical concern has emerged regarding patient adherence. A new study led by Washington University School of Medicine in St. Louis has found that the benefits of these drugs are not permanent once the medication is stopped. Following more than 333,000 U.S. veterans over three years, researchers discovered that stopping the medication for as little as six months significantly elevates the risk of major cardiovascular events. While weight regain is a visible consequence of stopping, the invisible "metabolic whiplash"—a resurgence in inflammation, blood pressure, and cholesterol—poses a far more lethal threat.

Quantifying the Cardiovascular Risk of Discontinuation

The study, published in BMJ Medicine, compared patients taking GLP-1s to those taking sulfonylureas, an older class of diabetes medication. The results showed that continuous use of GLP-1s over three years resulted in an 18% reduction in the risk of heart attack, stroke, and death. however, for patients who stopped the medication for one year, that benefit was entirely erased. Those who remained off the drugs for two years saw a 22% increase in cardiovascular risk compared to those who stayed on the treatment. Senior author Dr. Ziyad Al-Aly notes that the protection provided by these drugs builds slowly over time but erodes with alarming speed once the injections cease.

The Impact of Temporary Treatment Gaps

Even patients who eventually resumed their GLP-1 treatment faced long-term consequences from temporary gaps. The study found that an interruption of just six months led to a 4% to 8% increase in cardiovascular risk compared to continuous users. While restarting the medication helped restore some level of protection, it was only partial. This suggests that discontinuing the medication, even temporarily, leaves a "lasting scar" on the cardiovascular system that cannot be fully healed by resuming therapy. For clinicians, this highlights the necessity of viewing these medications as lifelong treatments for chronic conditions rather than short-term interventions.